Fulcrum Therapeutics, Inc.’s Price-to-Earnings Ratio at a glance
Fulcrum Therapeutics, Inc. reports price-to-earnings ratio of -30x for Dec 2024. The prior period recorded -4.3x (Dec 2023). Year over year the metric moved −25.7 (−604.6%). The rolling three-period average stands at -12.4x. Data last refreshed Dec 7, 2025, 2:46 AM.
Latest reading
-30x · Dec 2024
YoY movement
−25.7 (−604.6%)
Rolling average
-12.4x
Current Price-to-Earnings Ratio
-30x
−25.7
−604.6%
Rolling average
-12.4x
Latest Value
-30x
Dec 2024
YoY Change
−25.7
Absolute
YoY Change %
−604.6%
Rate of change
3-Period Avg
-12.4x
Smoothed
Narrative signal
Fulcrum Therapeutics, Inc.’s price-to-earnings ratio stands at -30x for Dec 2024. Year-over-year, the metric shifted by −25.7, translating into a −604.6% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How price-to-earnings ratio shapes Fulcrum Therapeutics, Inc.'s story
As of Dec 2024, Fulcrum Therapeutics, Inc. reports price-to-earnings ratio of -30x. Analyze price-to-earnings history, valuation swings, and relative multiples to benchmark market expectations.
Why the P/E ratio matters
The price-to-earnings multiple reveals how much investors are willing to pay for each dollar of net income. Elevated P/E levels suggest strong growth expectations or limited earnings.
Tracking valuation cycles
Monitoring multi-year P/E trends highlights how macro cycles, product launches, or profitability changes impact valuation over time.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
98%
Operating Margin
-27.4%
Net Profit Margin
-12.2%
Return on Equity
-4%
Return on Assets
-3.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Fulcrum Therapeutics, Inc. (FULC) FAQs
Answers tailored to Fulcrum Therapeutics, Inc.’s price-to-earnings ratio profile using the latest Financial Modeling Prep data.
What is Fulcrum Therapeutics, Inc.'s current price-to-earnings ratio?
As of Dec 2024, Fulcrum Therapeutics, Inc. reports price-to-earnings ratio of -30x. This reading reflects the latest filings and price data for FULC.
How is Fulcrum Therapeutics, Inc.'s price-to-earnings ratio trending year over year?
Year-over-year, the figure shifts by −25.7 (−604.6%). Pair this context with revenue growth and free cash flow signals to gauge momentum for FULC.
Why does price-to-earnings ratio matter for Fulcrum Therapeutics, Inc.?
The P/E ratio compares a company’s share price with its per-share earnings to gauge valuation. For Fulcrum Therapeutics, Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Fulcrum Therapeutics, Inc.'s price-to-earnings ratio above its recent average?
Fulcrum Therapeutics, Inc.'s rolling three-period average sits at -12.4x. Comparing the latest reading of -30x to that baseline highlights whether momentum is building or fading for FULC.
How frequently is Fulcrum Therapeutics, Inc.'s price-to-earnings ratio refreshed?
Data for FULC was last refreshed on Dec 7, 2025, 2:46 AM and updates automatically every 24 hours, keeping your valuation inputs current.